

Takeshi Kurose

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8959041/publications.pdf>

Version: 2024-02-01

19
papers

424
citations

623734

14
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

543
citing authors

#	ARTICLE	IF	CITATIONS
1	Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial. <i>Diabetologia</i> , 2016, 59, 453-461.	6.3	69
2	Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2012, 3, 70-79.	2.4	59
3	Clock gene defect disrupts light-dependency of autonomic nerve activity. <i>Biochemical and Biophysical Research Communications</i> , 2007, 364, 457-463.	2.1	36
4	Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycosylated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. <i>Journal of Diabetes Investigation</i> , 2012, 3, 464-467.	2.4	31
5	Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β -cell function. <i>Journal of Diabetes Investigation</i> , 2013, 4, 585-594.	2.4	25
6	Lifestyle changes as a result of COVID-19 containment measures: Bodyweight and glycemic control in patients with diabetes in the Japanese declaration of a state of emergency. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1718-1722.	2.4	25
7	Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin. <i>Diabetes Therapy</i> , 2012, 3, 14.	2.5	24
8	Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 442-447.	4.4	23
9	Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. <i>Journal of Diabetes Investigation</i> , 2014, 5, 445-448.	2.4	21
10	Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β -cell function and the achievement of the glycosylated hemoglobin target 1 year after initiation. <i>Journal of Diabetes Investigation</i> , 2018, 9, 822-830.	2.4	20
11	Dipeptidyl peptidase-4 inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. <i>Journal of Diabetes Investigation</i> , 2012, 3, 498-502.	2.4	18
12	Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining β -cell function and achievement of HbA1c target one year after initiation. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1203-1210.	2.3	17
13	Circadian rhythms and diabetes. <i>Journal of Diabetes Investigation</i> , 2011, 2, 176-177.	2.4	16
14	Relationship between deterioration of glycosylated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1153-1158.	2.4	14
15	Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 2162-2171.	2.4	12
16	Mental distress and health-related quality of life among type 1 and type 2 diabetes patients using self-monitoring of blood glucose: A cross-sectional questionnaire study in Japan. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1203-1211.	2.4	9
17	Evaluation of large-scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs. <i>Journal of Diabetes Investigation</i> , 2017, 8, 633-634.	2.4	3
18	Reply to the comment of Wilbrink <i>et al.</i> on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β -cell function and the achievement of the HbA1c target 1 year after initiation. <i>Journal of Diabetes Investigation</i> , 2018, 9, 981-983.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Effects of physicianâ€™s diabetes selfâ€management education using Japan Association of Diabetes Education and Care Diabetes Education Card System Program and a selfâ€monitoring of blood glucose readings analyzer in individuals with type 2 diabetes: An exploratory, openâ€labeled, prospective randomized clinical trial. <i>Journal of Diabetes Investigation</i> , 2021, . . .	2.4	0